![](https://investorshub.advfn.com/uicon/574814.png?cb=1611948086)
Friday, February 16, 2024 2:18:54 PM
Recent XERS News
- Xeris to Participate in Upcoming Investor Conferences • Business Wire • 08/22/2024 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/09/2024 08:06:56 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 08/08/2024 08:27:40 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/08/2024 11:15:47 AM
- Xeris Biopharma Reports Second Quarter 2024 Financial Results • Business Wire • 08/08/2024 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/02/2024 09:22:39 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 08/02/2024 09:16:53 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/02/2024 08:14:16 PM
- Xeris Biopharma to Report Second Quarter 2024 Financial Results on August 8, 2024 • Business Wire • 07/25/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/08/2024 11:14:32 AM
- Xeris Biopharma Announces CEO Succession Plan • Business Wire • 07/08/2024 11:00:00 AM
- Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) • Business Wire • 07/03/2024 05:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/05/2024 08:19:36 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/05/2024 08:15:27 PM
- Xeris Presents New Post Hoc Analysis on Effects of Levoketoconazole (Recorlev®) in Cushing’s Syndrome Patients at ENDO 2024 • Business Wire • 06/03/2024 11:00:00 AM
- Xeris Biopharma Announces Positive Topline Phase 2 Clinical Data of Its Investigational XeriSol™-Formulated Once-Weekly Subcutaneous (SC) Levothyroxine (XP-8121) • Business Wire • 05/30/2024 11:30:00 AM
- Xeris to Participate in the Jefferies Global Healthcare Conference • Business Wire • 05/30/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 11:14:33 AM
- Xeris Biopharma Reports First Quarter 2024 Financial Results and Recent Events • Business Wire • 05/09/2024 11:00:00 AM
- Xeris Enters Into an Exclusive Worldwide Collaboration and License Agreement with Beta Bionics • Business Wire • 05/06/2024 11:00:00 AM
- Xeris Biopharma to Report First Quarter 2024 Financial Results on May 9, 2024 • Business Wire • 05/02/2024 11:00:00 AM
- Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) • Business Wire • 04/03/2024 08:05:00 PM
- Xeris Biopharma to Participate in the 23rd Annual Needham Virtual Healthcare Conference • Business Wire • 04/02/2024 11:00:00 AM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 03/06/2024 09:19:18 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/06/2024 09:10:13 PM
Element79 Gold Corp Appoints Warren Levy to Board of Directors • ELMGF • Aug 28, 2024 9:51 AM
Integrated Ventures Announces Strategic Entry Into Health & Wellness Industry with Focus on GLP-1 Products • INTV • Aug 28, 2024 8:30 AM
ELEMENT79 ANNOUNCES UPLISTING TO OTCQB VENTURE MARKET • ELMGF • Aug 26, 2024 10:03 AM
North Bay Resources Announces Gold Assays up to 2.2 Ounces per Ton, Fran Gold Project, British Columbia • NBRI • Aug 26, 2024 10:00 AM
PickleJar Unveils Latest Venue Managed Services Innovations in Upcoming Webinar • PKLE • Aug 23, 2024 1:11 PM
Element79 Gold Corp Provides Update on Nevada Portfolio • ELMGF • Aug 23, 2024 8:00 AM